Dr. Du is a genetic epidemiologist studying inherited and modifiable factors in cancer—particularly colorectal, endometrial, and pancreatic cancers. This work, conducted in collaboration with international research teams, seeks to understand tumorigenesis and identify individuals who could most benefit from targeted lifestyle modifications or preventive interventions. Dr. Du studies colorectal cancer biology, risk factors, and risk modeling: With colleagues in the African Research Group in Oncology (ARGO), she co-leads a NIH-funded study of risk factors and tumor mutation profiles for colorectal cancers in Nigeria. She also studies genetic and epidemiologic predictors as well as colorectal tumor biology in European descent individuals using data in the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO). Dr. Du investigates endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium (E2C2), for which she is PI of the Data Coordinating Center and an Executive Committee member. She co-leads a NIH-funded study in this population that will use multiethnic tumor profiling to provide insights into the 2-fold higher mortality in Black patients. Dr. Du also studies pancreatic cancer surveillance and risk factor identification: She co-leads, with an MSK gastroenterologist, the MSK Pancreatic Tumor Registry—which since 2002 has continuously performed surveillance and followed at-risk unaffected relatives of pancreatic cancer patients. The Registry also enrolled patients with pancreatic cancer or with intraductal papillary mucinous neoplasms (IPMNs) and cancer-free controls for risk factor studies. Finally, Dr. Du studies telomere dynamics in various large, population-based data sources. She co-directs the MSK Quantitative Sciences Summer Undergraduate Research Experience (QSURE). She also serves on the Scientific Committee for the New York City Epidemiology Forum and is an Associate Editor for the international journal Cancer Causes & Control.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Mengmeng (Margaret) Du discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.
View all disclosures